COVID-19 vaccines for African countries?

22 January 2021 | Story Benjamin Kagina. Photo Pexels / Sam Moqadam . Read time 6 min.
Key questions about COVID-19 vaccines for Africa need to be answered to dispel prevalent misinformation.
Key questions about COVID-19 vaccines for Africa need to be answered to dispel prevalent misinformation.

Vaccines for COVID-19 are generating a lot of talk. To shed some light on which vaccines are available for countries in sub-Saharan Africa, and how the process will work, The Conversation Africa’s Ina Skosana and Ozayr Patel asked Benjamin Kagina to answer a few questions.

What’s immediately available for African countries?

African health regulatory authorities must approve the use of vaccines before they can be rolled out on the continent. National health regulatory authorities around the continent are working closely with regional and global regulatory bodies to ensure the approval processes will be efficient.

The AstraZeneca-Oxford vaccine was approved for emergency use by the UK health regulator on 30 December 2020 and will be available for use in Africa once regulators on the continent approve it. It is likely that the approval will be obtained in the first quarter of 2021. This vaccine was also tested in parts of the continent like South Africa.

At the time of writing, South Africa had secured 1.5 million doses of AstraZeneca-Oxford vaccine from the Serum Institute of India which is producing these vaccines for low- and middle-income countries. The national regulator is in the process of reviewing the relevant vaccine data in order to grant approval for its emergency use in the country.

The African Vaccine Acquisition Task Team established by African Union Chair President Cyril Ramaphosa recently secured a provisional 270 million vaccine doses for African countries. The vaccines will be supplied by AstraZeneca-Oxford, Pfizer-BioNTech and Johnson & Johnson. The distribution of these vaccines on the continent will likely depend on the population size of each country. Even with additional 600 million vaccine doses promised by the World Health Organisation’s COVAX facility, the cumulative total vaccine doses available will only be enough for about half of the continent’s population.

Another vaccine that is likely to be available to the continent soon is that manufactured by Moderna. Pfizer-BioNTech and Moderna vaccines have already been approved for emergency use by the US as well as UK health regulators.

What about offerings from Russia and China?

The Gamaleya Research Institute of Epidemiology and Microbiology in Russia and Sinopharm in China allowed the public use of their vaccines before conducting large-scale clinical trials. This raised huge public concerns.

Conducting clinical trials and openly sharing the data from the trials is the international standard practice. The practice is to conduct three phases, all with smaller scale tests at first. Results from such trials are reviewed to assess safety and efficacy. This always precedes regulatory approval. If this route isn’t followed it is unlikely these vaccines will get approval from the national health regulators as there is no data to review.

Nevertheless, countries are buying vaccines from China. The Financial Times is also reporting that countries are buying Russia’s Sputnik V vaccine while the two leading Chinese manufacturers, Sinopharm and Sinovac Biotech, have signed deals with more than a dozen countries.

But public safety and scrutiny is critical. Without data from the trials it will be difficult to get the public on board. Sinopharm has submitted clinical data to the World Health Organisation for review.

Which will be easiest to deliver in developing countries?

When Pfizer-BioNTech announced that their vaccine was 95% effective, they also said it had to be stored at a temperature of -70℃. Most low-income countries do not have the necessary cold chain infrastructure for storing and distributing this vaccine.

Vaccines that require standard refrigeration conditions, like many of those used in existing immunisation programmes in these countries, would be easiest to deliver. The AstraZeneca-Oxford vaccine is one.

Johnson & Johnson has also developed a vaccine being trialled in Africa. The phase III results for this vaccine will be available in February 2021. If the vaccine is proven to be safe and effective, it will be the easiest to distribute as it requires the standard refrigeration. And more importantly, it requires just one dose, which is logistically easier to deliver.

Will new COVID-19 variants affect roll-out plans?

At present, it is thought that the mutations will not affect the efficacy of the vaccines. But more data is still required to be sure about this. Scientists and vaccine manufacturers are assessing if the current vaccines are effective against the new variants. Preliminary data are encouraging.

The roll-out is therefore continuing and tests will continue to assess if the emerging variants affect the vaccines’ efficacy.

Why there is so much concern about how quickly the vaccines were developed?

There is a lot of misinformation and incorrect messaging on social media platforms about the new vaccines. One incorrect message is that the vaccines were short-circuited and that this could have compromised them. It is important to emphasise that due diligence was adhered to and no short cuts were taken. These vaccines were tested properly and are proved to be safe. Additional monitoring of safety is ongoing as the vaccines get rolled out to more people following approval by the regulators. Safety monitoring will remain a key component of the vaccines roll-out.The Conversation

Benjamin Kagina, Senior Research Officer, Vaccines For Africa Initiative, Faculty of Health Sciences, University of Cape Town.

This article was published in The Conversation, a collaboration between editors and academics to provide informed news analysis and commentary. Its content is free to read and republish under Creative Commons; media who would like to republish this article should do so directly from its appearance on The Conversation, using the button in the right-hand column of the webpage. UCT academics who would like to write for The Conversation should register with them; you are also welcome to find out more from

For licensing information please visit the source website.

UCT’s response to COVID-19 in 2021

COVID-19 is a global pandemic that caused President Cyril Ramaphosa to declare a national disaster in South Africa on 15 March 2020 and to implement a national lockdown from 26 March.

UCT is taking the threat of infection in our university community extremely seriously, and this page will be updated regularly with the latest COVID-19 information. Please note that the information on this page is subject to change depending on current lockdown regulations.

Frequently asked questions


Daily updates

Friday, 5 February 14:20, 5 February 2021
Monday, 4 January 16:50, 4 January 2021
Friday, 18 December 11:30, 18 December 2020
Thursday, 19 November 09:30, 19 November 2020
Friday, 13 November 12:40, 13 November 2020
Friday, 16 October 10:05, 16 October 2020
Wednesday, 14 October 12:50, 14 October 2020
Tuesday, 22 September 14:10, 22 September 2020
Friday, 11 September 10:05, 11 September 2020
Monday, 31 August 12:20, 31 August 2020
Wednesday, 12 August 10:20, 12 August 2020
Friday, 7 August 11:24, 7 August 2020
Thursday, 6 August 18:26, 6 August 2020
Monday, 27 July 14:00, 27 July 2020
Wednesday, 15 July 09:30, 15 July 2020
Monday, 13 July 14:25, 13 July 2020
Monday, 6 July 16:20, 6 July 2020
Thursday, 25 June 10:15, 25 June 2020
Tuesday, 23 June 12:30, 23 June 2020
Thursday, 18 June 17:35, 18 June 2020
Wednesday, 17 June 10:45, 17 June 2020
Tuesday, 2 June 12:20, 2 June 2020
Friday, 29 May 09:25, 29 May 2020
Monday, 25 May 14:00, 25 May 2020
Thursday, 21 May 12:00, 21 May 2020
Wednesday, 6 May 10:00, 6 May 2020
Tuesday, 5 May 17:05, 5 May 2020
Thursday, 30 April 17:10, 30 April 2020
Tuesday, 28 April 10:30, 28 April 2020
Friday, 24 April 09:35, 24 April 2020
Thursday, 23 April 17:00, 23 April 2020
Wednesday, 22 April 14:25, 22 April 2020
Monday, 20 April 17:45, 20 April 2020
Friday, 17 April 12:30, 17 April 2020
Thursday, 16 April 09:45, 16 April 2020
Tuesday, 14 April 11:30, 14 April 2020
Thursday, 9 April 09:00, 9 April 2020
Wednesday, 8 April 15:40, 8 April 2020
Wednesday, 1 April 15:50, 1 April 2020
Friday, 27 March 11:40, 27 March 2020
Thursday, 26 March 18:30, 26 March 2020
Tuesday, 24 March 15:40, 24 March 2020
Monday, 23 March 15:40, 23 March 2020
Friday, 20 March 16:00, 20 March 2020
Thursday, 19 March 09:15, 19 March 2020
Wednesday, 18 March 16:00, 18 March 2020
Tuesday, 17 March 12:50, 17 March 2020
Monday, 16 March 17:15, 16 March 2020

Campus communications



New SRC and other updates 16:44, 4 November 2020
Virtual graduation ceremonies 13:30, 21 October 2020
Online staff assembly and other updates 15:09, 30 September 2020
Fee adjustments and other updates 15:21, 16 September 2020
Call for proposals: TLC2020 10:15, 26 August 2020
SAULM survey and other updates 15:30, 5 August 2020
COVID-19 cases and other updates 15:26, 5 August 2020
New UCT Council and other updates 15:12, 15 July 2020
Upcoming UCT virtual events 09:30, 15 July 2020
Pre-paid data for UCT students 14:25, 22 April 2020
Update for postgraduate students 12:55, 20 April 2020
UCT Human Resources and COVID-19 16:05, 19 March 2020
UCT confirms second COVID-19 case 09:15, 19 March 2020
Update on UCT COVID-19 response 13:50, 11 March 2020
Update on COVID-19 17:37, 6 March 2020


Video messages from the Department of Medicine

Getting credible, evidence-based, accessible information and recommendations relating to COVID-19

The Department of Medicine at the University of Cape Town and Groote Schuur Hospital, are producing educational video material for use on digital platforms and in multiple languages. The information contained in these videos is authenticated and endorsed by the team of experts based in the Department of Medicine. Many of the recommendations are based on current best evidence and are aligned to provincial, national and international guidelines. For more information on UCT’s Department of Medicine, please visit the website.

To watch more videos like these, visit the Department of Medicine’s YouTube channel.

Useful information from UCT

External resources

News and opinions

Statements and media releases

Media releases

Read more  

Statements from Government


In an email to the UCT community, Vice-Chancellor Professor Mamokgethi Phakeng said:
“COVID-19, caused by the virus SARS-CoV-2, is a rapidly changing epidemic. [...] Information [...] will be updated as and when new information becomes available.”


We are continuing to monitor the situation and we will be updating the UCT community regularly – as and when there are further updates. If you are concerned or need more information, students can contact the Student Wellness Service on 021 650 5620 or 021 650 1271 (after hours), while staff can contact 021 650 5685.